Blinatumomab Plus Consolidation Chemotherapy Significantly Reduces Risk of Death in MRD-Negative B-Cell ALLDecember 19th 2022
Blinatumomab plus consolidation chemotherapy demonstrated a survival advantage for patients with newly diagnosed minimal residual disease–negative B-cell acute lymphoblastic leukemia.
Improved PFS Outcomes With Elacestrant Correlate With CDK4/6 Duration in ER+/HER2– Metastatic Breast CancerDecember 17th 2022
Longer duration of CDK4/6 inhibitor prior to treatment with elacestrant correlated with progression-free survival (PFS) improvements in patients with estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer vs standard-of-care options.
TKIs Do Not Add Protective Benefit Against Peripheral Neuropathy in Patients With ALL Receiving VincristineDecember 16th 2022
Patients with acute lymphoblastic leukemia who received vincristine-based regimens with TKIs did not experience more chemotherapy-induced peripheral neuropathy vs those who did not.
Challenges Faced by Adolescent and Young Adult Patients With Cancer
Adolescents and young adults who have cancer also have a negative body image, financial toxicity, and concerns about family planning.
Phase 3 Data Support Leaving the “Neutrodiet” Behind After Stem Cell TransplantDecember 15th 2022
A nonrestrictive diet was found to be noninferior to a protective diet in the post-stem cell transplant setting, suggesting that lifting restrictions may improve patient quality of life.
Upfront Dostarlimab/Chemotherapy Yields Better Risk Reduction Than Pembrolizumab/Chemotherapy in NSCLCDecember 14th 2022
Patients with metastatic non-squamous non–small cell lung cancer who received frontline dostarlimab (Jemperli) plus chemotherapy experienced a risk of disease progression or death that was 30% greater than that experienced with pembrolizumab (Keytruda).
Adjuvant Chemotherapy Does Not Significantly Increase Breast Cancer-Related Lymphedema RiskDecember 13th 2022
Treatment with chemotherapy, including taxane-based chemotherapies, in the adjuvant setting did not yield significant differences in breast-cancer related lymphedema risk.
Adagrasib Receives Accelerated Approval for KRAS G12C Mutated NSCLCDecember 13th 2022
Adagrasib has received accelerated approval for KRAS G12C mutated non–small cell lung cancer. The prescribing label comes with warnings for gastrointestinal toxicities, QTC interval prolongation, hepatotoxicity, and interstitial lung disease.
Ovarian Suppression Treatment Is Rare for Premenopausal Women with HR+/HER2+ Breast CancerDecember 12th 2022
In real-world practice, use of ovarian suppression therapy was not common among premenopausal patients with hormone receptor–positive, HER2-positive breast cancer, with tamoxifen being the preferred endocrine therapy.
Real-World Patient-Reported Outcomes for Axi-Cel Align With Clinical Trial QOL, Symptomology DataDecember 11th 2022
Real-world data from patient-reported outcomes suggest that axicabtagene ciloleucel is associated with temporary worsening of quality of life with statistically and clinically significant improvements within 1-year postinfusion.
Daratumumab-Quadruplet Therapy Yields Promising HRQOL Scores in Transplant Eligible, Newly Diagnosed, Multiple MyelomaDecember 11th 2022
Adding daratumumab to bortezomib, lenalidomide, and dexamethasone showed meaningful improvements in patient-reported outcomes in the phase 2 GRIFFIN trial.
DESTINY-Breast02 Confirms Benefit of Trastuzumab Deruxtecan in Previously Treated Patients With HER2+ Metastatic Breast CancerDecember 10th 2022
In the second-line setting, patients with advanced HER2-positive breast cancer derived a superior clinical benefit with trastuzumab deruxtecan compared with treatment with physician’s choice of treatment.
Adjuvant Abemaciclib Plus Endocrine Therapy Sustains Benefit for Patients With HR+/HER2– High-Risk Early Breast CancerDecember 9th 2022
A landmark 4-year analysis of invasive-disease free survival outcomes from the phase 3 monarchE study support the use of adjuvant abemaciclib with endocrine therapy for patients with hormone receptor–positive, HER2-negative, node-positive early breast cancer.
Trastuzumab Deruxtecan Outperforms Trastuzumab Emtansine in DESTINY-Breast03 Follow-UpDecember 8th 2022
Trastuzumab deruxtecan both significantly improved overall survival and yielded progression-free survival that was 4 times greater than trastuzumab emtansine in patients with HER2-positive metastatic breast cancer.
Cancer Has No Gender: Challenging Assumptions and Improving Quality of Care for the LGBTQ+ CommunityDecember 7th 2022
Improve care for LGBTQ+ patients with cancer by learning about disparities, focusing on patient-centered treatment, and not making assumptions about patients and their loved ones.
Futibatinib Approval Ushers in Targeted Therapy Option for Patients With Unresectable, Intrahepatic FGFR2-Positive CholangiocarcinomaDecember 6th 2022
Osheka Hansel, APRN, discusses the recent approval of futibatinib (Lytgobi) for patients with unresectable, locally advanced or metastatic intrahepatic FGFR2-positive cholangiocarcinoma.
Opinion: The Good Nurse Brings Safe Narcotic Handling to the Forefront of Nursing MindsDecember 6th 2022
Sometimes nurses inappropriately handle high-risk medications. It is important that other nurses, especially those who work in pain management, hold colleagues accountable to promote patient safety.